两种剂量分割模式碳离子放射治疗肺癌淋巴引流区临床报告

doi:10.3760/cma.j.cn113030-20220401-00119

摘要
图/表
参考文献(16)
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要目的比较采用相对生物效应（RBE）剂量48 Gy,16次和12次分割碳离子束照射局部晚期非小细胞肺癌（LA‐NSCLC）淋巴结引流区的不良反应、有效性及生存率。方法收集2020年6月至2021年12月甘肃省武威肿瘤医院重离子中心收治的病理确诊为LA‐NSCLC的患者72例,简单随机法分为A组、B组各36例,分别给予A组48 Gy（RBE）分16次和B组48 Gy（RBE）分12次碳离子束选择野照射淋巴结引流区,观察其急慢性不良反应、有效性及生存率。采用Kaplan‐Meier法绘制生存曲线,log‐rank法进行差异检验。结果 A、B组中位随访时间分别为13.9（8.8~15.7）、14.6（6.3~15.9）个月,治疗有效分别为16例（44.4%）、9例（25.0%）,疾病控制分别为34例（94.4%）、30例（83.3%）。统计分析显示A、B组总生存率的差异无统计学意义（χ²=1.192,P=0.275）。两组患者放疗计划参数比较显示,CTV体积,患侧肺D_mean、V_{5 Gy（RBE）}、V_{20 Gy（RBE）}、V_{30 Gy（RBE）},心脏V_{20 Gy（RBE）}、V_{30 Gy（RBE）}、D_mean,食管V_{30 Gy（RBE）}、V_{50 Gy（RBE）}、D_max、D_mean,气管D_max,脊髓D_max等相关指标的差异均无统计学意义（P值均>0.05）。纳入患者在治疗期间及随访过程中均未出现3、4级不良反应;两组患者1、2级急性放射性皮肤反应（χ²=5.134,P=0.077）、放射性食管炎（χ²=1.984,P=0.371）、晚期放射性肺炎（χ²=6.185,P=0.103）发生情况的差异均无统计学意义。结论碳离子放疗系统两种剂量分割模式在LA‐NSCLC纵隔淋巴结引流区选择野照射治疗中安全性相近,不良反应可控,远期疗效仍需进一步观察。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	潘鑫
	张一贺
	李小军
	马彤
	王馨
	杨钰玲
	柴鸿钰
	秦天燕
	吕彩霞
	李鹏庆
	叶延程
	张雁山

关键词 ：放射疗法,碳离子, 癌,非小细胞肺, 选择性淋巴结引流区放疗, 不良反应, 近期疗效

Abstract：Objective To compare the adverse reactions, efficacy and survival rate of carbon ion beam irradiation in the elective lymph node (ENI) drainage area of locally advanced non‐small cell lung cancer (LA‐NSCLC) with relative biological effect (RBE) dose of 48 Gy using 16 and 12 fractions. Methods A total of 72 patients with pathologically confirmed LA‐NSCLC admitted to Wuwei Heavy Ion Center of Gansu Wuwei Tumor Hospital from June 2020 to December 2021 were enrolled and simple randomly divided into groups A and B, with 36 patients in each group. Patients in groups A and B were treated with carbon ion beam irradiation to the lymph node drainage area with 48 Gy (RBE) using 16 and 12 fractions. The acute and chronic adverse reactions, efficacy and survival rate were observed. The survival curve was drawn by Kaplan‐Meier method. Difference test was conducted by log‐rank test. Results The median follow‐up time was 13.9 (8.8‐15.7) months in group A and 14.6 (6.3‐15.9) months in group B. Sixteen (44.4%) patients were effectively treated in group A and 9 (25%) patients in group B. Thirty‐four (94.4%) cases achieved disease control in group A and 30 (83.3%) cases in group B. Statistical analysis showed that the overall survival rate in group B was similar to that in group A (χ²=1.192, P=0.275). Comparison of planning parameters between two groups showed CTV volume, D_mean, V_{5 Gy(RBE)}, V_{20 Gy(RBE)} and V_{30 Gy(RBE)} of the affected lung, cardiac V_{20 Gy(RBE)}, V_{30 Gy(RBE)} and D_mean, esophageal V_{30 Gy(RBE)}, V_{50 Gy(RBE)}, D_max and D_mean, D_max of the trachea and spinal cord had no significant difference (all P>0.05). No grade 3 or 4 adverse reactions occurred in the enrolled patients during treatment and follow‐up. No statistical differences were observed in the acute radiation skin reaction (χ²=5.134, P=0.077), radiation esophagitis (χ²=1.984, P=0.371), and advanced radiation pneumonia (χ²=6.185, P=0.103) between two groups. Conclusions The two dose fractionation modes of carbon ion therapy system are equally safe in the mediastinal lymphatic drainage area of LA‐NSCLC, and the adverse reactions are controllable. The long‐term efficacy still needs further observation.

Key words： Radiotherapy,carbon ion Carcinoma,non‐small cell lung Elective lymph node drainage area radiotherapy Adverse reactions Short‐term efficacy

收稿日期: 2022-04-01

基金资助:甘肃省科技重点研发计划‐社会发展类重离子治疗中心项目建设（19YF3FH001）; 甘肃省自然科学基金‐2021年甘肃省科技厅创新基地和人才计划项目（21JR7RH896）

通讯作者: 张雁山,Email：13830510999@163.com

引用本文:

潘鑫,张一贺,李小军等. 两种剂量分割模式碳离子放射治疗肺癌淋巴引流区临床报告[J]. 中华放射肿瘤学杂志, 2023, 32(3): 215-221.

Pan Xin,Zhang Yihe,Li Xiaojun et al. Clinical report of two dose fractionation modes using carbon ion beam therapy in the lymph node drainage area for lung cancer[J]. Chinese Journal of Radiation Oncology, 2023, 32(3): 215-221.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.cn113030-20220401-00119 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2023/V32/I3/215

[1] Takahashi W, Nakajima M, Yamamoto N, et al.A prospective nonrandomized phase I/II study of carbon ion radiotherapy in a favorable subset of locally advanced non-small cell lung cancer (NSCLC)[J]. Cancer, 2015,121(8):1321-1327. DOI: 10.1002/cncr.29195.
[2] Verhagen AF, Bulten J, Shirango H, et al.The clinical value of lymphatic micrometastases in patients with non-small cell lung cancer[J]. J Thorac Oncol, 2010,5(8):1201-1205. DOI: 10.1097/JTO.0b013e3181e29ace.
[3] Sulman EP, Komaki R, Klopp AH, et al.Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer[J]. Radiat Oncol, 2009,4:5. DOI: 10.1186/1748-717X-4-5.
[4] Lee CB, Stinchcombe TE, Rosenman JG, et al.Therapeutic advances in local-regional therapy for stage III non-small-cell lung cancer: evolving role of dose-escalated conformal (3-dimensional) radiation therapy[J]. Clin Lung Cancer, 2006,8(3):195-202. DOI: 10.3816/CLC.2006.n.047.
[5] Perez CA, Stanley K, Rubin P, et al. A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the Radiation Therapy Oncology Group[J]. Cancer, 1980,45(11):2744-2753. DOI: 10.1002/1097-0142(19800601)45:11<2744::aid-cncr2820451108>3.0.co;2-u.
[6] Emami B, Mirkovic N, Scott C, et al.The impact of regional nodal radiotherapy (dose/volume) on regional progression and survival in unresectable non-small cell lung cancer: an analysis of RTOG data[J]. Lung Cancer, 2003,41(2):207-214. DOI: 10.1016/s0169-5002(03)00228-9.
[7] Machtay M, Paulus R, Moughan J, et al.Defining local-regional control and its importance in locally advanced non-small cell lung carcinoma[J]. J Thorac Oncol, 2012,7(4):716-722. DOI: 10.1097/JTO.0b013e3182429682.
[8] Li RJ, Yu L, Lin SX, et al.Involved field radiotherapy (IFRT) versus elective nodal irradiation (ENI) for locally advanced non-small cell lung cancer: a meta-analysis of incidence of elective nodal failure (ENF)[J]. Radiat Oncol, 2016,11(1):124. DOI: 10.1186/s13014-016-0698-3.
[9] Wang SL, Liao ZX, Wei X, et al.Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT)[J]. Int J Radiat Oncol Biol Phys, 2006,66(5):1399-1407. DOI: 10.1016/j.ijrobp.2006.07.1337.
[10] Durante M, Loeffler JS.Charged particles in radiation oncology[J]. Nat Rev Clin Oncol, 2010,7(1):37-43. DOI: 10.1038/nrclinonc.2009.183.
[11] Saitoh JI, Shirai K, Abe T, et al.A phase I study of hypofractionated carbon-ion radiotherapy for stage III non-small cell lung cancer[J]. Anticancer Res, 2018,38(2):885-891. DOI: 10.21873/anticanres.12298.
[12] Takahashi W, Nakajima M, Yamamoto N, et al.A prospective nonrandomized phase I/II study of carbon ion radiotherapy in a favorable subset of locally advanced non-small cell lung cancer (NSCLC)[J]. Cancer, 2015,121(8):1321-1327. DOI: 10.1002/cncr.29195.
[13] Hayashi K, Yamamoto N, Karube M, et al.Prognostic analysis of radiation pneumonitis: carbon-ion radiotherapy in patients with locally advanced lung cancer[J]. Radiat Oncol, 2017,12(1):91. DOI: 10.1186/s13014-017-0830-z.
[14] Bradley JD, Paulus R, Komaki R, et al.Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study[J]. Lancet Oncol, 2015,16(2):187-199. DOI: 10.1016/S1470-2045(14)71207-0.
[15] Kaster TS, Yaremko B, Palma DA, et al.Radical-intent hypofractionated radiotherapy for locally advanced non-small-cell lung cancer: a systematic review of the literature[J]. Clin Lung Cancer, 2015,16(2):71-79. DOI: 10.1016/j.cllc.2014.08.002.
[16] Hayashi K, Yamamoto N, Nakajima M, et al.Clinical outcomes of carbon-ion radiotherapy for locally advanced non-small-cell lung cancer[J]. Cancer Sci, 2019,110(2):734-741. DOI: 10.1111/cas.13890.